Webinar :Register now for Commodity Ki Paathshala webinar on ‘FPOs & Agriculture Marketing-The Beginning of a New Era’ on January 22, 4pm

'After lockdown, V-shaped recovery possible in auto, NBFCs, private banks, metals'

Auto, auto ancillaries, NBFCs, private banks, and metals will witness recovery, says Umesh Mehta of Samco Securities.

April 10, 2020 / 11:24 AM IST

A V-shaped recovery is likely in most beaten-down stocks and sectors. Auto, auto ancillaries, NBFCs, private banks, and metals will witness recovery as the pent-up demand is likely to compensate for the lost days, Umesh Mehta, Head of Research, Samco Securities, says in an interview to Moneycontrol’s Kshitij Anand.

Edited excerpts:

Q) It was comparatively a better week for Indian markets but what is the way forward? What are the reasons for the rally – stimulus hopes, a drop in coronavirus cases?

A) Indian markets are aping the US and other global indices, as there is a revival in confidence with regards to fighting this pandemic. Many countries are showing a reduction in COVID-19-related cases and this is boosting sentiment.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Another factor that led to the rally this week was the fact that the lockdown period is coming to an end. Whether this period will be extended is anybody’s guess, but for now, investors’ hopes are up that most of the negatives are already factored in.

Q) What are the factors that investors should watch out for in the coming week, which again will be a truncated one? Initial reports suggest that the lockdown will be extended in the metros, will that be a spoiler?

A) Investors are hawk-eyed to the news on the extension of the lockdown. This will be the deciding factor that will guide bourses in the coming week.

Any surprises will cause the indices to move either with a gap-up or a gap-down. Global cues will also be a major force for the markets in the coming week. Traders should be extremely cautious and take bets only if they have a high-risk appetite.

Q) Small & midcaps have outperformed. Is it value buying which is leading to the outperformance or the liquidity factor, which is not enough in some of these names when compared to largecaps?  

A) Buying is more event-driven at this point than value-driven. Investors are following the ‘buy-on-dips’ strategy but in the process, they are forgetting that companies that have performed in the past are not necessarily going to emerge winners post this pandemic.

It is extremely essential to analyse the impact of lockdowns and restrictions in trade on businesses before buying them.

Since there is uncertainty in how long the lockdown will last or if it will be extended, it is too early to assess the gravity of the crisis.

Q) One thing which we cannot close our eyes to is “recession” and the coronavirus outbreak. Both the events are interlinked and will have a lasting impact on the economies across the world, including India. What are your views?

A) Markets and the economy, in general, have witnessed recessions once every decade. It is indeed a tough time as this pandemic is not due to a financial crisis but is a health hazard.

Hence, the impact will be much larger, affecting varied industries. Recessions are tough times with job losses, shut down in small businesses and the steeper the fall, the longer time it will take for economies to revive just like it has in the past.

Hence, only risk-taking investors who have the patience to remain invested for a good five years should start accumulating equities.  It will not be advisable for the faint-hearted to venture into the market when the VIX is at 51 while the lower range is 30.

Q) Which are the companies that are likely to see a V-shaped recovery after the lockdown?

A) A V-shaped recovery in stock prices can be witnessed in most beaten-down stocks and sectors. Auto, auto ancillaries, NBFCs, private banks, and metals will witness recovery as the pent-up demand is likely to compensate for the lost days.

There may be a postponement in demand but nonetheless demand will remain for such companies. FMCG, as a sector, will not be attractive from investing point of view because of high valuations and the fact that a bullish consensus is already built into prices.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Kshitij Anand is the Editor Markets at Moneycontrol.

stay updated

Get Daily News on your Browser
Sections